Ontology highlight
ABSTRACT: Background and purpose
The involvement of astrocytes as immune-competent players in inflammation and the pathogenesis of epilepsy and seizure-induced brain damage has recently been recognized. In clinical trials and practice, levetiracetam (LEV) has proven to be an effective antiepileptic drug (AED) in various forms of epileptic seizures, when applied as mono- or added therapy. Little is known about the mechanism(s) of action of LEV. Evidence so far suggests a mode of action different from that of classical AEDs. We have shown that LEV restored functional gap junction coupling and basic membrane properties in an astrocytic inflammatory model in vitro.Experimental approach
Here, we used neonatal rat astrocytes co-cultured with high proportions (30%) of activated microglia or treated with the pro-inflammatory cytokine interleukin-1? to provoke inflammatory responses. Effects of LEV (50 µg·mL?¹) on electrophysiological properties of astrocytes (by whole cell patch clamp) and on secretion of TGF?1 (by (ELISA)) were studied in these co-cultures.Key results
LEV restored impaired astrocyte membrane resting potentials via modification of inward and outward rectifier currents, and promoted TGF?1 expression in inflammatory and control co-cultures. Furthermore, LEV and TGF?1 exhibited similar facilitating effects on the generation of astrocyte voltage-gated currents in inflammatory co-cultures and the effects of LEV were prevented by antibody to TGF?1.Conclusions and implications
Our data suggest that LEV is likely to reduce the harmful spread of excitation elicited by seizure events within the astro-glial functional syncytium, with stabilizing consequences for neuronal-glial interactions.
SUBMITTER: Stienen MN
PROVIDER: S-EPMC3031068 | biostudies-literature | 2011 Jan
REPOSITORIES: biostudies-literature
Stienen Martin N MN Haghikia Aiden A Dambach Hannes H Thöne Jan J Wiemann Martin M Gold Ralf R Chan Andrew A Dermietzel Rolf R Faustmann Pedro M PM Hinkerohe Daniel D Prochnow Nora N
British journal of pharmacology 20110101 2
<h4>Background and purpose</h4>The involvement of astrocytes as immune-competent players in inflammation and the pathogenesis of epilepsy and seizure-induced brain damage has recently been recognized. In clinical trials and practice, levetiracetam (LEV) has proven to be an effective antiepileptic drug (AED) in various forms of epileptic seizures, when applied as mono- or added therapy. Little is known about the mechanism(s) of action of LEV. Evidence so far suggests a mode of action different fr ...[more]